Cardiovascular Complications of COVID-19 in Patients with Multiple Sclerosis: A Lesson from Our Experience

COVID-19 is an emerging threat which could affect the cardiovascular system in the setting of cytokine-storm syndrome. The objective of this study is to screen the cardiac injury associated with COVID-19 in patients with multiple sclerosis (MS).

We analyzed 6 cases of multiple sclerosis in association with COVID-19 who underwent cardiac evaluation within hospitalization. The mean age of our patients was 36.6 years old. Two patients had SPMS, one patient had PPMS and the rest of patients had RRMS. Our patients were on both immunomodulatory and immunosuppressive DMTs. None of our patients had a cardiovascular risk factor or developed cardiovascular complications. The electrocardiogram, echocardiography and cardiac enzymes were within normal. The mean course of the hospitalization was 11.8 days. After a month of follow up, all patients returned to their baseline neurological status except the one with PPMS and moderate COVID-19 who developed a 0.5 point progression of EDSS score.

patients with MS might be at risk to develop severe COVID-19 in which cardiac injury is a crucial complication. There are limited data describing myocarditis associated with COVID-19 in patients with MS.

our cases revealed no evidence of cardiac injury in patients with MS even on immunosuppressive DMTs.